Merck’s Oral Cholesterol Pill, Enlicitide, Achieves 60% LDL Reduction, Matching Injectable Efficacy
Merck’s new oral cholesterol pill, enlicitide, achieved up to 60% LDL reduction in Phase 2 trials, matching injectable PCSK9 efficacy. Read the full analysis.